拉米夫定（Lamivudine）是一种新型的核苷类似物，进入人体肝细胞内可形成三磷酸衍生物，作用于乙肝病毒（HBV）聚合酶，阻止病毒DNA的合成、可望不久正式在临床推广应用。拉米夫定治疗慢性乙型肝炎的推荐剂量为每日日眼lling，疗程初步定为1年，拉米夫定口服后能很好吸收，可 Lamivudine, a novel nucleoside analogue, enters the body’s liver cells to form triphosphate derivatives that act on hepatitis B virus (HBV) polymerase to prevent the synthesis of viral DNA and are expected to be formalized shortly after Clinical application. The recommended dose of lamivudine for treatment of chronic hepatitis B is daily eye lling, the initial course of treatment was set at 1 year, lamivudine can be well absorbed after oral administration, but